FDA Inspection 1053263 — InvaGen Pharmaceuticals, Inc.

InvaGen Pharmaceuticals, Inc. — FEI 3003950641

The FDA completed an inspection of InvaGen Pharmaceuticals, Inc. on May 25, 2018 in Hauppauge, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
May 25, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Hauppauge, NY (United States)

Citations

IDCFRDescription
125621 CFR 211.68(b)Backup file not maintained
191221 CFR 211.166(a)Written program not followed
202721 CFR 211.192Investigations of discrepancies, failures
360321 CFR 211.160(b)Scientifically sound laboratory controls
890621 CFR 314.81(b)(1)(i)Mix-up
891121 CFR 314.81(b)(1)(ii)Failure to meet specifications